Member Info for HarChris

I should have said outgrown AIM. Hence the need to partner up here and command non-dilutive funding + possible Nasdaq path.

Only a small minority of AIM businesses reach Avacta’s £350m mcap and they aren’t usually cash hungry biotechs.

We have been bailed out by the tin price and to a lesser extent lithium price over the past six months, before of which have kept interest here and prevented any major sell off.

But it’s now time AV made the most of the backdrop and delivered the cash flows at Uis that we absolutely should be seeing. Clock is ticking, anything less than 10p by the end of the year will be a real let down.

AIM is fine. It is what it is, it wasn’t designed for companies with Avacta’s potential.

We’ll still see a buyout at an appropriate price here on AIM if that’s what it requires.

I said 6103 preliminary not before June. Where are they?

Where are the up-to-date AVA6000 P1 clinical results that I was assured by certain belligerent rampers would be revealed in a May presentation?

_______

Is this a joke? Are you on a wind up?

Absolutely nobody (sensible, just in case there’s some idiot you can quote) expected any prelim 6103 data this half year.

The up-to-date 6000 results is for ASCO which IS in May.

I TOLd EVERYONE that AVaCTA WOUldNt Be BOUGHT OUT FOR $200 trillion in APzrIL but no one is ADMITTING im a GENiuS.

With how close ASCO is and a hoped for deal on top of such consistent superb preclinical data across programmes I’m confident we don’t see a big sell off today. Maybe a drop first thing then finish blue.

This really is spammy.

Nothing obscene whatsoever and at a price higher than recent trading. Nothing to see here.

A strong move in Au over the past twenty four hours, fingers crossed this continues and then news soon on multiple fronts.

This second batch of 7 holes shows consistent results with the first batch (15 holes) with similar grades and good continuity at depth. Also reinforcing the polymetallic element again adds huge value with tin grades and tantalum likely higher than Uis as a simple byproduct.

From what I understand there are thinner zones that require additional drilling and that’s why the drill campaign is being expanded but that’s also to be expected. Would like more of the results to have been released here (as certainly have drilled more than 22 holes) but hopefully they land consistently now over the coming months.

Got to give it to this management team, they’re doing all they can to excite the market and stimulate further investment.

TD there are plenty of tungsten explorers that have 5 to 10 bagged in the last year, well before reaching production.

I don’t know, those 5 trades are odd but the share price does seem to have found its bottom unless gold goes on to sink a lot lower from here.. A tad below the last placing price with the 2026 that’s to come looks like a very decent entry point for newbies and those thinking to add.

It honestly couldn’t be better despite the poor execution on the tin at Uis end. And essentially what that’s cost us is the dilution of the most recent placing that would otherwise have been covered with cash / a far higher sp/ lower dilution.

Frustrating but not existential and now there’s no balance sheet issues to hold us back - finally delivering on the tin scale will be transformational here. Come on AV time to deliver!

ECR Digital. Was an attempt to leverage the bitcoin treasury hype last year. Might end up seeing attempt numero dos in the future.

If the answer is ‘essentially zero’ then you have your answer. For reasons discussed ad infinitum P1a for the inaugural drug took a long while but looking forward now everything is moving far faster (BOIN for 6103) and we wait to see what developments follow the p1b release.

Could you let us know how many drugs gain fda approval in phase 1?

Have faith in Mr Helium himself Bo to get things right against a backdrop of what will be sky high helium prices for a long while to come.

At least you have your health.

It's perfectly reasonable to be doubtful re execution and hence choose to invest your money elsewhere. It's a bit weird to hang around repeating it and repeating it.

There are plenty of shares i'm less convinced will be successful than the holders so i remain a viewer from the sidelines and share my thoughts on said shares only occasionally.

The time to buy may well be after the next cash injection but expect it to be quite sizeable considering the low cash figure and the bond maturities this year - £10m perhaps?

'Thats why I think it impossible to have even a remotely sensible conversation'

______________

Maybe you should look within. Or at least sidestep the debate if that's your default position as you will just automatically dismiss others without thought.

This is small cap biotech investing, the goal is to prove the technology so as to get bought out and commanding as high a valuation as possible. It's always a rollercoaster and there were points when Avacta could have fallen by the wayside before they even had the chance to prove the tech but that's in the rearview mirror now, they are too close backed against a high enough mcap to ensure that this is decided by the science now.

You seem to be looking for certainty where there isn't any. Biotech investing is extremely high risk/high reward but Avacta is at least differentiated in as much as they've crossed off many of the unknowns that make such investments high risk and because of it there is now reason to be confident that this is going to ultimately be successful. Is it a guarantee? Of course not, there's no such thing as a 10+ bagger certainty but I'm with those now that think the risk/reward is the best out there and worth the oversized position i'm sure many others like me now have.

If you don't fine but being a contrarian whilst admitting that you don't understand so much of it really doesn't add much to the debate.